Chemring Group (LSE:CHG) is benefiting from Europe's defence rearmament mainly through Demand for energetics, the specialist explosives and propellant materials that go into missiles, munitions and countermeasures. As NATO members commit to much higher defence budgets and prioritise sovereign Supply chains, Chemring has signed long-term supply agreements with European prime contractors and is investing heavily to expand capacity, notably at its Chemring Nobel site in Norway.
The results so far show strong demand but also the cost of building for it. In interim results for the six months to 30 April 2026, published on 2 June, Chemring reported a record order book of £1,399 million, up 8 per cent year on year, and Revenue up 6.5 per cent to £237.3 million. Underlying operating profit fell 7.5 per cent to £24.5 million, however, as its Sensors and Information Business had a weaker half and Capital spending pushed net Debt higher.
Management left full-year expectations unchanged and said profit would be weighted about 70 per cent to the second half. A change of chief executive is also approaching.
Two businesses serving defence customers
Chemring reports in two segments. Countermeasures and Energetics makes decoy flares and chaff that protect aircraft and ships from missiles, alongside energetic materials, propellants and pyrotechnic devices used in weapons. Sensors and Information includes its UK technology business Roke, which works in cyber, electronic warfare and data science, and US operations making chemical and biological threat detection equipment.
The group says more than half of revenue comes from single-supplier arrangements. The UK government accounted for about 15.8 per cent of revenue in the year to 31 October 2025, according to the annual report, with the US Department of Defense and allied governments among other key customers.
How European rearmament feeds the order book
The Annual Report for 2025 noted that European defence spending reached a record €326 billion in 2024, with a further €100 billion increase projected by 2027, and that NATO members have pledged to raise defence spending to 5 per cent of GDP by 2035. In the interim statement, management described NATO spending as structurally elevated, with priorities including munitions stockpiles, integrated air defence, drones and cyber, and said European governments are prioritising sovereign capability and secure supply chains.
Chemring Nobel is the most direct beneficiary. It has agreed a twelve-year framework with Germany's Diehl Defence carrying an initial order of €231 million for MCX energetic material, with deliveries from 2027. It also has a £36 million three-year agreement to supply HMX to Saab in Switzerland from 2028 to 2030, and a £23 million ten-year HMX agreement with Nammo running from 2027 to 2037.
The Countermeasures and Energetics segment is already reflecting this demand. In the first half its revenue rose 9.1 per cent to £142.1 million and underlying operating profit increased 31.8 per cent to £26.1 million, lifting the Margin to 18.4 per cent from 15.2 per cent. Its order book stood at £1,274 million.
Building capacity, and paying for it
To meet demand, Chemring is expanding energetics production in the US, the UK and Norway. It invested £44 million of Capital Expenditure in the first half. A Chicago Facility is complete and ramping up, a Scottish site is being commissioned and the Norwegian project is moving into its next phase. The company expects the programme to add around £100 million of annual revenue and £30 million of operating profit by 2028.
Costs have risen along the way. The annual report put expected gross costs of the Norwegian expansion at £180 million, up from £145 million, offset by £90 million of grant funding, leaving a net spend by Chemring of about £90 million. Net debt rose to £144.5 million at 30 April 2026 from £93.3 million a year earlier.
The company's longer-term ambition, set out in the 2025 annual report, is to roughly double revenue to about £1 billion by 2030, from £497.5 million in the year to October 2025.
Where the pressure lies
The Sensors and Information segment had a difficult half. Revenue rose 2.8 per cent to £95.2 million, but underlying operating profit fell 40.4 per cent to £9.6 million and the margin dropped to 10.1 per cent from 17.4 per cent. Chemring also recorded a £6.7 million Impairment linked to retiring legacy countermeasures production in Tennessee, and closed its Alloy Surfaces special materials business in Philadelphia after US demand fell significantly, despite contract awards announced in June.
In the UK, management pointed to near-term fiscal pressures and said publication of the Defence Investment Plan is expected to normalise government order placement. Other risks the company highlights include changes in customer ordering patterns and budget delays, supply chain vulnerabilities, currency and Interest Rate movements, and geopolitical shifts. Execution risk on large capacity projects is significant, as the Norwegian cost increase shows.
There have been positives elsewhere. On 1 July Chemring's US sensors business won a single-supplier contract for the Joint Biological Tactical Detection System, with a $48.8 million ceiling and an initial $36.3 million production order. The CORTEXA counter-drone system, launched in April 2026, has secured early international sales in Sweden and the UK.
Dividend, buyback and leadership
The interim Dividend was raised 4 per cent to 2.8p, following a total of 8.0p for 2025. Chemring had bought back 2.0 million shares for £8.7 million by April 2026 under a programme running to the 2027 annual general meeting, and it targets dividend cover of about 2.5 times underlying earnings.
On 30 July the company announced that Michael Ord will retire as group chief executive on 1 January 2027 after eight years. Tom Newman, who spent 17 years at Babcock International and most recently led a £1 billion revenue defence and engineering services business there, joins as chief executive designate on 5 October 2026.
What to watch
Key milestones include delivery of the heavily second-half-weighted profit for the year to 31 October 2026, progress in commissioning the Scottish and Norwegian energetics expansions, any recovery in Sensors and Information margins, and the handover to Newman. The conclusion of a Norwegian feasibility study into a new military explosives facility, expected in late 2026, is also on the agenda.
The Bottom Line
Chemring is one of the more direct listed UK plays on European rearmament, with a record order book, long-term contracts with major European defence groups and a clear programme to expand energetics capacity. The first half of 2026 showed energetics profits rising strongly. Against that, group profit fell, net debt climbed, Sensors and Information weakened and a new chief executive will soon take charge. Turning demand into sustained profit growth will depend on delivering new capacity on time and on budget.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...